Table 1.
Refinement of definitions of comorbidities
| Comorbidity | CCI definition | New definition, from HCT-CI |
|---|---|---|
| Mild pulmonary | Dyspnea on moderate activity | Dyspnea on moderate activity or DLco and/or FEV1 81%-90% |
| Moderate pulmonary | Dyspnea on slight activity | Dyspnea on slight activity or DLco and/or FEV1 66%-80% |
| Severe pulmonary | Dyspnea at rest or requires oxygen | Dyspnea at rest or requires oxygen or DLco and/or FEV1 ≤ 65% |
| Cardiac | Congestive heart failure (symptomatic and requiring treatment) and myocardial infarction were included as independent comorbidities, each acquiring a score of 1 | Includes coronary artery disease,* congestive heart failure, myocardial infarction, or ejection fraction ≤ 50%: one or more acquiring a score of 1 |
| Mild hepatic | Chronic hepatitis or cirrhosis | Chronic hepatitis, bilirubin > ULN to 1.5 × ULN, or AST/ALT > ULN to 2.5 × ULN |
| Moderate-severe hepatic | Cirrhosis with portal hypertension ± bleeding varices | Cirrhosis, fibrosis, bilirubin > 1.5 × ULN, or AST/ALT > 2.5 × ULN |
| Mild renal | Serum creatinine 2-3 mg/dL | Creatinine 1.2-2 mg/dL |
| Moderate-severe renal | Creatinine > 3 mg/dL, renal dialysis, or renal transplant | Creatinine > 2 mg/dL, renal dialysis, or renal transplant |
| Prior solid tumor | Initially treated in the last 5 y | Treated at any time point in the patient's past history, excluding nonmelanoma skin cancer |
To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.
DLco indicates diffusion capacity of carbon monoxide; FEV1, forced expiratory volume in one second; ULN, upper limit of normal; AST, aspartate aminotransferase; and ALT, alanine aminotransferase.
*
One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.